Q3 EPS Estimates for Pyxis Oncology Increased by Analyst

Key Points

• HC Wainwright has raised its Q3 2025 earnings estimate for Pyxis Oncology to ($0.37) EPS, improving from the previous estimate of ($0.40), while maintaining a "Buy" rating with a price target of $5.00.
• Pyxis Oncology recently reported earnings of ($0.30) per share for the last quarter, exceeding the consensus estimate of ($0.36) by $0.06, with revenues totaling $2.82 million.
• Zacks Research has upgraded Pyxis Oncology's rating from "strong sell" to "hold", while it currently has a consensus rating of "Moderate Buy" and a price target of $8.67.

Pyxis Oncology, Inc. (NASDAQ:PYXS - Free Report) - Equities researchers at HC Wainwright increased their Q3 2025 EPS estimates for Pyxis Oncology in a research report issued to clients and investors on Tuesday, August 19th. HC Wainwright analyst S. Ramakanth now anticipates that the company will post earnings per share of ($0.37) for the quarter, up from their prior estimate of ($0.40). HC Wainwright currently has a "Buy" rating and a $5.00 target price on the stock. The consensus estimate for Pyxis Oncology's current full-year earnings is ($1.04) per share. HC Wainwright also issued estimates for Pyxis Oncology's Q4 2025 earnings at ($0.41) EPS, FY2025 earnings at ($1.42) EPS, Q1 2026 earnings at ($0.42) EPS, Q2 2026 earnings at $0.33 EPS, Q3 2026 earnings at ($0.34) EPS, Q4 2026 earnings at ($0.36) EPS, FY2026 earnings at ($1.35) EPS, FY2027 earnings at ($1.28) EPS, FY2028 earnings at ($0.57) EPS and FY2029 earnings at $0.20 EPS.

Pyxis Oncology (NASDAQ:PYXS - Get Free Report) last released its quarterly earnings data on Thursday, August 14th. The company reported ($0.30) EPS for the quarter, beating analysts' consensus estimates of ($0.36) by $0.06. The firm had revenue of $2.82 million during the quarter.

Several other research analysts also recently commented on PYXS. Zacks Research raised shares of Pyxis Oncology from a "strong sell" rating to a "hold" rating in a research note on Monday, August 18th. Wall Street Zen raised shares of Pyxis Oncology from a "sell" rating to a "hold" rating in a research report on Sunday. Three research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $8.67.

Pyxis Oncology Stock Performance

Pyxis Oncology stock traded down $0.05 during mid-day trading on Thursday, hitting $1.35. 119,137 shares of the company traded hands, compared to its average volume of 550,897. Pyxis Oncology has a one year low of $0.83 and a one year high of $5.39. The stock has a market cap of $83.42 million, a price-to-earnings ratio of -0.84 and a beta of 1.13. The stock has a fifty day moving average price of $1.16 and a 200-day moving average price of $1.15.

Hedge Funds Weigh In On Pyxis Oncology

Institutional investors have recently made changes to their positions in the company. ProShare Advisors LLC purchased a new position in shares of Pyxis Oncology during the fourth quarter valued at $26,000. Catalyst Funds Management Pty Ltd purchased a new position in shares of Pyxis Oncology during the second quarter valued at $26,000. Ameriprise Financial Inc. purchased a new position in Pyxis Oncology in the fourth quarter valued at about $35,000. Caption Management LLC purchased a new position in Pyxis Oncology in the fourth quarter valued at about $35,000. Finally, Kingstone Capital Partners Texas LLC purchased a new position in Pyxis Oncology in the second quarter valued at about $37,000. Hedge funds and other institutional investors own 39.09% of the company's stock.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.